MetaCap

Eledon Pharmaceuticals (ELDN) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eledon Pharmaceuticals is the larger company by market cap ($150.3 million vs $149.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELDN-32.06%RNA-53.08%
+67%+2%-62%
Feb 27, 20261 yearNov 20, 2026
ELDN-32.06%RNA-53.08%
+61%+1%-59%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELDN versus RNA key metrics
MetricELDNRNA
Share price$1.78$6.92
Market cap$150.34M$149.27M
1-day change-6.32%-0.86%
YTD return+17.88%—
1-year return+23.61%—
5-year return-65.64%—
EPS (TTM)$-0.73$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-45.62M—
52-week high$4.49$16.77
52-week low$1.39$6.36
Distance from 52-week high-60.36%-58.74%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+405.62%+217.92%
Average volume931.77K297.20K
Shares outstanding84.46M21.57M
Employees33—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eledon Pharmaceuticals

ELDN stock →

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

ELDN vs RNA FAQ

Which is bigger, Eledon Pharmaceuticals or Atrium Therapeutics?

Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $150.34M compared with $149.27M for Atrium Therapeutics (RNA).

Are Eledon Pharmaceuticals and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons